

ongoing trials - trial from www.clinicaltrials.gov

AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis - Not yet recruiting

Code: NCT07608328 **Year:** 2026 **Date:** 2026

Author: Assiut University

Study design (if review, criteria of inclusion for studies)

The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).

Participants

The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).

Interventions

Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER)

Outcome measures

The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).

<https://clinicaltrials.gov/study/NCT07608328>

Keywords

Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; pharmacological_intervention;